Communiqués ContraFect Corporation

Actions

CFRXQ

US2123264093

Recherche biotechnologique et médicale

Marché Fermé - OTC Markets 16:53:43 08/09/2026			Varia. 5j.	Varia. 1 janv.
0,000001 ^USD	-99,00%		0,00%	-

05/12/23	ContraFect Corporation annonce la démission de ses dirigeants	CI
05/12/23	ContraFect Corporation annonce la démission de Michael Messinger en tant que directeur général	CI

Communiqués

14/11/23	ContraFect: Q3 Earnings Snapshot	AQ
16/10/23	ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical Study	AQ
19/09/23	ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development	AQ
18/09/23	ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370	AQ
28/08/23	ContraFect to Present at the World Anti-Microbial Resistance Congress 2023	AQ
16/08/23	ContraFect : Q2 2023 Investor Presentation	PU
14/08/23	ContraFect: Q2 Earnings Snapshot	AQ
14/08/23	ContraFect Reports Second Quarter 2023 Financial Results and Provides Business Update	AQ
27/06/23	ContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 Million	AQ
20/06/23	CONTRAFECT CORP : Submission of Matters to a Vote of Security Holders (form 8-K)	AQ
20/06/23	ContraFect Data Presentations at ASM Microbe 2023 Demonstrate the Power of the Company’s Proprietary Platform to Discover New Agents Targeting Antibiotic-Resistant Gram-negative Pathogens	AQ
08/06/23	ContraFect to Present New Data Demonstrating the Potential Efficacy of Its Engineered Lysins Against Antibiotic-Resistant Pathogens at ASM Microbe 2023	AQ
15/05/23	ContraFect: Q1 Earnings Snapshot	AQ
15/05/23	ContraFect Reports First Quarter 2023 Financial Results and Provides Business Update	AQ
26/04/23	ContraFect Announces First Patient Dosed in the Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee	AQ
20/04/23	ContraFect Data Presentations at the 33rd Annual ECCMID Meeting Highlight the Potential Efficacy of Lysin CF-370 Against Antibiotic Resistant Gram-negative Pathogens	AQ
18/04/23	CONTRAFECT CORP : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
06/04/23	ContraFect Announces Multiple Presentations of New Data at the 33rd Annual ECCMID Meeting	AQ
03/04/23	ContraFect Announces Initiation of a Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee	AQ
31/03/23	CONTRAFECT CORP Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	AQ
31/03/23	ContraFect: Q4 Earnings Snapshot	AQ
31/03/23	ContraFect Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Provides Business Update	AQ
02/03/23	CONTRAFECT CORP : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
28/02/23	ContraFect Announces Pricing of $10.0 Million Registered Direct Offering and Concurrent Private Placement	AQ
14/02/23	CONTRAFECT CORP : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	AQ